胆管癌靶向药佩米替尼(达伯坦)可显著提高疾病控制率

Cholangiocarcinoma is a malignant tumor that occurs in the bile duct system, and its causes may be related to bile duct stones, primary sclerosing cholangitis and other diseases. The main clinical manifestations include: jaundice, abnormal bowel movements, gallbladder enlargement, liver damage, biliary infection, and biliary bleeding. Pemetinib (Dabotan) is a potent and selective oral inhibitor targeting FGFR subtypes 1/2/3. The drug has been approved by the FDA and has good clinical effects on patients with advanced, previously treated cholangiocarcinoma carrying FGFR2 gene fusions or other rearrangements.

Pemetinib (Dabotan) treatment effect

A clinical trial evaluated the efficacy of pemetinib (dalbertam) in 108 patients with surgically unresectable locally advanced, recurrent, or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement who had failed at least one line of systemic therapy.

The trial results showed that the objective response rate (ORR) was 37%, the median duration of response (DOR) was 8.08 months, of which 66% of patients had a duration of response (DOR) greater than or equal to 6 months, and 37.5% of patients had a duration of response (DOR) greater than 12 months.

Another clinical trial was conducted in China. Among 30 patients with evaluable efficacy, the objective response rate (ORR) was 50% and the disease control rate reached 100%. Pemetinib (Dabotan) can improve the response rate and disease control rate, prolong the duration of response, and has a significant effect in the treatment of cholangiocarcinoma. The launch of this drug has brought new treatment options and options to many patients with cholangiocarcinoma.

The above is an introduction to Pemetinib (Dabotan). If patients want to know more about the latest drug information about this drug (such as the price of Pemetinib, how to purchase, precautions, usage, etc.), they can contact the Medical Companion Travel Service at any time.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: